Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Ublituximab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 187 days left·Open·Supplies
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Ublituximab, ATC L04AG14

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

Submission by original document is required and electronic submission is not allowed, which increases the risk of late...

The buyer reserves the right to replace the open-house contracts with exclusive rebate agreements during the term, whic...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive rebate agreements for pharmaceutical products containing Ublituximab (ATC L04AG14).
  • Open-house model with uniform conditions for all participants and no individual negotiations.
Pokaż pełne podsumowanie

Open-house supply arrangement for the active substance Ublituximab (ATC L04AG14) offered by AOK Rheinland-Pfalz/Saarland. It is a non-exclusive, no-selection contract model with uniform terms for all participants, no individual negotiations, and monthly entry possible during the 24-month term. The notice states that this publication is not a public contract in the sense of procurement law, but it is published in TED for transparency. No contract value is provided.

Ryzyka

Submission by original document is required and electronic submission is not allowed, which increases the risk of late...

The buyer reserves the right to replace the open-house contracts with exclusive rebate agreements during the term, whic...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Only authorised and legally marketable medicines in Germany may be supplied.

Administrative

  • If a medicine is not yet listed in Lauer-Taxe at submission time, an AMIce public extract must be provided.
  • The AMIce extract must show name, marketing authorisation holder or authorised manufacturer, dosage form, active substance, and marketability.

Zamawiający

Lokalizacja

Eisenberg, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE271900642

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Ublituximab

Single lot covering non-exclusive pharmaceutical rebate agreements for medicines containing Ublituximab. The open-house model applies uniform terms to all participating pharmaceutical companies. Children’s medicines listed in the BfArM list under Section 35(5a) SGB V are excluded. Contract start is earliest 2025-05-01, with monthly entry possible during the 24-month period; contracts end no later than 24 months after the earliest start date. The lot information comes from structured data and the TED XML notice.

SuppliesEU fundedElectronic submission

Lokalizacja

Eisenberg, Germany

Czas trwania

Apr 2025 - Apr 2027

Kategoria

Pharmaceutical products

Termin

Deadline Feb 28, 2027

Szczegóły zamówienia

Data publikacji
26 Mar 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
196730-2025

Dokumenty (1)

Podobne przetargi